
Signs of a patient influx recovery for Coloplast’s segment have appeared – particularly in Europe, where the patient numbers are almost the same as prior to the Covid-10 pandemic, says the medtech company’s CEO, Kristian Villumsen, in an interview with MarketWire.
However, he says there are still challenges outside Europe, particularly in the US, where the inflow of new patients in Coloplast’s Continence Care business continues to lag behind, and also in China, where consumer pattern have changed, resulting in reduced sales.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app